Tracking Warren Buffett's Berkshire Hathaway Portfolio - Q3 2020 Update

John Vincent profile picture
John Vincent


  • Berkshire Hathaway's 13F stock portfolio value increased from ~$202B to ~$229B this quarter.
  • Their largest three holdings are at two-thirds of the entire portfolio.
  • Berkshire Hathaway reduced financials while adding several positions in the Big Pharma area.

This article is part of a series that provides an ongoing analysis of the changes made to Berkshire Hathaway’s 13F stock portfolio on a quarterly basis. It is based on Warren Buffett’s regulatory 13F Form filed on 11/16/2020. Please visit our Tracking 10 Years Of Berkshire Hathaway's Investment Portfolio article series for an idea on how his holdings have progressed over the years and our previous update for the moves in Q2 2020.

During Q1 2020, Berkshire Hathaway’s (NYSE:BRK.A, NYSE:BRK.B) 13F stock portfolio value increased ~13%, from ~$202B to ~$229B. The top five positions account for more than three-quarters of the portfolio: Apple Inc. (AAPL), Bank of America (BAC), Coca-Cola (KO), American Express (AXP), and Kraft Heinz (KHC). There are 46 individual stock positions, many of which are minutely small compared to the overall size of the portfolio.

Warren Buffett’s writings (pdfs) are a treasure trove of information and are a very good source for anyone starting out on individual investing.

Note 1: In Q3 2020, Berkshire Hathaway repurchased ~45M Class B Equivalent Shares, for a total outlay of $9.26B. The average price paid was ~$206. Book Value as of Q3 2020 was ~$174 per share. So, the repurchase happened at ~118% of Book Value. The Class B shares currently trade at ~$233.

Note 2: It was reported in August that Berkshire had invested 5% passive stake each in 5 Japanese trading companies.

New Stakes

AbbVie Inc. (ABBV), Merck & Company (MRK), Bristol-Myers Squibb (BMY), and Pfizer Inc. (PFE): Berkshire added these four picks from the Big Pharma sector this quarter. ABBV, MRK, and BMY received an allocation of ~$1.8B each, while the PFE stake is much smaller at ~$135M. ABBV traded between ~$86 and ~$101 during the quarter, and it currently goes for $98.36. MRK traded between ~$77 and ~$87 during the quarter, and it currently goes for $80.18. BMY traded between ~$57.50 and ~$63.75 during the quarter, and

This article was written by

John Vincent profile picture
Focused on cloning strategies by analyzing 13F reports of a curated set of around fifty super-investors and generating Absolute Returns thru exploiting inefficiency, volatility, and momentum.

Disclosure: I am/we are long ABBV, AMZN, KHC, WFC, BRK.B. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (46)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.